- SCPH Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
8-K Filing Data
scPharmaceuticals (SCPH) 8-K12 Jul 22Study results favor FUROSCIX® versus “treatment as usual” in composite primary endpoint and all secondary endpointsFinancial data
Company Profile